Genzyme’s license from AGTC related to only one program: gene therapy for wet AMD.
Possibly. SNY’s close partnership with REGN could have played a role, but the discontinued AMD program had other problems, IMO.
AGTC’s AAV-vector technology has improved in the eight years since the AMD deal was struck with Genzyme, so I don’t consider the Genzyme history a significant blemish for AGTC.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.